最新ニュース MariMed (OTC:MRMD) 株価情報

MariMed

MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees and Licensing fees.

Analyst Color

Cannabis

Market Summary

News

Penny Stocks

Small Cap Analysis

Retail Sales

Success Stories

Exclusives

Markets

Analyst Ratings

Trading Ideas

Interview

General

MRMD

シニアアナリストのPablo・Zuanic氏が、マリメド社（OTC:MRMD）CEOのJon Levine氏とのファイヤーサイドチャットを進行し、同社の事業、成長戦略および財務見通しについて透視した。この議論は、大麻投資家にとって有益な情報を提供している。

マリメド社　大麻投資家にとって重要な議論を提供

MariMed Inc

Whales with a lot of money to spend have taken a noticeably bullish stance on Analog Devices.
Looking at options history for Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $275,604 and 5, calls, for a total amount of $196,440.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $230.0 for Analog Devices, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Analog Devices's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Analog Devices's substantial trades, within a strike price spectrum from $180.0 to $230.0 over the preceding 30 days.
<h3>Analog Devices 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732652427_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$6.9</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$217.50</td>
<td>$65.0K</td>
<td>163</td>
<td align="right">112</td>
</tr>
<tr>
<td>ADI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.7</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$230.00</td>
<td>$60.0K</td>
<td>1.1K</td>
<td align="right">30</td>
</tr>
<tr>
<td>ADI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.9</td>
<td>$2.55</td>
<td>$2.55</td>
<td>$210.00</td>
<td>$47.1K</td>
<td>1.8K</td>
<td align="right">501</td>
</tr>
<tr>
<td>ADI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$4.4</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$222.50</td>
<td>$40.0K</td>
<td>166</td>
<td align="right">195</td>
</tr>
<tr>
<td>ADI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.8</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$190.00</td>
<td>$39.9K</td>
<td>70</td>
<td align="right">200</td>
</tr>
</tbody>
</table>

<h3>About Analog Devices</h3>
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
After a thorough review of the options trading surrounding Analog Devices, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Analog Devices</h3>
<ul>
<li>Currently trading with a volume of 4,673,920, the ADI's price is down by -3.07%, now at $216.71. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>What Analysts Are Saying About Analog Devices</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $220.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Wells Fargo lowers its rating to Equal-Weight with a new price target of $220.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Analog Devices, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Market Whales and Their Recent Bets on ADI Options

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 41%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $735,359, and 4 are calls, for a total amount of $167,575.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $700.0 and $800.0 for Regeneron Pharmaceuticals, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale activity within a strike price range from $700.0 to $800.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732652422_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$78.7</td>
<td>$78.3</td>
<td>$78.7</td>
<td>$780.00</td>
<td>$173.0K</td>
<td align="right">102</td>
<td align="right">22</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$60.0</td>
<td>$58.3</td>
<td>$58.3</td>
<td>$700.00</td>
<td>$104.9K</td>
<td align="right">210</td>
<td align="right">103</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$60.0</td>
<td>$57.9</td>
<td>$57.9</td>
<td>$700.00</td>
<td>$98.4K</td>
<td align="right">210</td>
<td align="right">103</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$60.0</td>
<td>$57.9</td>
<td>$57.9</td>
<td>$700.00</td>
<td>$92.6K</td>
<td align="right">210</td>
<td align="right">103</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$60.0</td>
<td>$58.3</td>
<td>$58.3</td>
<td>$700.00</td>
<td>$81.6K</td>
<td align="right">210</td>
<td align="right">103</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
In light of the recent options history for Regeneron Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Regeneron Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a trading volume of 444,007, the price of REGN is down by -0.82%, reaching $743.4.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1116.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1126. 
&#x2A; An analyst from Citigroup downgraded its action to Neutral with a price target of $895. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1215. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1195. 
&#x2A; In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $1150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

REGN

Regeneron Pharmaceuticals Unusual Options Activity

Financial giants have made a conspicuous bullish move on Airbnb. Our analysis of options history for Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) revealed 10 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $62,488, and 8 were calls, valued at $564,556.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $120.0 to $200.0 for Airbnb during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Airbnb's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Airbnb's whale trades within a strike price range from $120.0 to $200.0 in the last 30 days. 
<h3>Airbnb 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732652417_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$24.2</td>
<td>$24.05</td>
<td>$24.2</td>
<td>$140.00</td>
<td>$193.6K</td>
<td>564</td>
<td align="right">80</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.0</td>
<td>$7.1</td>
<td>$140.00</td>
<td>$112.0K</td>
<td>4.2K</td>
<td align="right">268</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$11.2</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$130.00</td>
<td>$88.0K</td>
<td>1.9K</td>
<td align="right">119</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$45.15</td>
<td>$44.55</td>
<td>$44.55</td>
<td>$120.00</td>
<td>$44.5K</td>
<td>68</td>
<td align="right">10</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$140.00</td>
<td>$35.5K</td>
<td>4.2K</td>
<td align="right">164</td>
</tr>
</tbody>
</table>

<h3>About Airbnb</h3>
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of Sept. 30, 2024. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
In light of the recent options history for Airbnb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Airbnb's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,899,097, with ABNB's price down by -0.95%, positioned at $139.59.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 77 days.</li>
</ul>
<h3>What The Experts Say On Airbnb</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $141.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for Airbnb, targeting a price of $155. 
&#x2A; An analyst from Benchmark has revised its rating downward to Buy, adjusting the price target to $155. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Airbnb, targeting a price of $145. 
&#x2A; An analyst from Phillip Securities downgraded its action to Reduce with a price target of $120. 
&#x2A; Consistent in their evaluation, an analyst from DA Davidson keeps a Neutral rating on Airbnb with a target price of $131. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Airbnb, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ABNB

A Closer Look at Airbnb's Options Market Dynamics

WIIM

Abercrombie & Fitch shares are trading lower after the company reported Q3 financial results.

<a href="https://docs.fcc.gov/public/attachments/DA-24-1193A1.pdf" title="https://docs.fcc.gov/public/attachments/DA-24-1193A1.pdf">https://docs.fcc.gov/public/attachments/DA-24-1193A1.pdf</a>

DXYZ

FCC Grants SpaceX Right To Some Direct-To-Cellular Operations

CD Projekt ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTGLY#OTC">OTGLY</a>) has announced that Project Polaris, the first installment in a new Witcher trilogy, has transitioned from preproduction to <a href="https://www.benzinga.com/general/gaming">full-scale production. </a>
"I'm proud to confirm that several weeks ago the Polaris team wrapped up preproduction and moved on to full-scale production – the most intensive phase of development," <a href="https://www.cdprojekt.com/en/media/news/cd-projekt-wraps-up-the-third-quarter-of-2024/">sai</a>d Michał Nowakowski, joint CEO of CD Projekt. "We are very pleased with our progress on this project, and I wish to thank the team for its dedication."
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42198567/19000-bans-and-counting-but-players-say-cheating-still-dominates-call-of-duty-black-ops-6">19,000 Bans And Counting, But Players Say Cheating Still Dominates Call Of Duty Black Ops 6</a>
About 400 of the company's 650 developers are focused on <a href="https://www.benzinga.com/general/gaming/23/11/36008635/with-a-major-focus-on-the-witcher-4-whats-cd-projekt-red-crafting-next">Project Polaris</a>. 
CD Projekt is working to ensure the game is ready for its planned 2025 release, following a preproduction phase that began in May 2022.
 "I'm thrilled to announce that Project Polaris has entered the full-scale production phase,&#8221; Sebastian Kalemba, the game director, added. &#8220;With new challenges just around the corner, it's the talented and hard-working people who make me believe we can together make the upcoming Witcher Saga a remarkable experience. No stopping now! Stay tuned for what's on the other side of the coin!"
<h3 class="wp-block-heading">CD Projekt Reports Strong Q3 Performance, Cyberpunk 2077 Continues To Thrive</h3>
In its third-quarter 2024 financial report, CD Projekt revealed impressive revenue figures. The company reported revenues of 228 million PLN (approximately $53.76 million) and a consolidated net profit of 78 million PLN.
In addition to work on Project Polaris, CD Projekt is <a href="https://www.benzinga.com/general/gaming/24/08/40639564/cd-projekt-profits-surge-90-cyberpunk-2077-the-witcher-3-drive-109-million-in-sales">seeing success</a> with its current titles. 
The studio reported that Cyberpunk 2077 has sold over 30 million copies, and the Phantom Liberty expansion has sold over eight million copies since its release. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42169267/how-baldurs-gate-3-turned-larian-studios-into-a-447-million-powerhouse">How Baldur&#8217;s Gate 3 Turned Larian Studios Into A $447 Million Powerhouse</a></li>
</ul>

Gaming

OTGLY

Project Polaris Hits Full-Scale Production: What's Next For The Witcher And CD Projekt?

A cease-fire deal to end the fighting between Israel and the militant group Hezbollah in Lebanon is 
What Happened: The short-term proposal is to pause hostilities for 60 days but with the intention of a lasting truce, according to <a href="https://www.cnn.com/world/live-news/israel-hezbollah-ceasefire-deal-gaza-war-11-26-24-intl-hnk/index.html">CNN</a>, which cited an Israeli official. 
Prime Minister Benjamin Netanyahu offered three reasons for the cease fire, one being to shift focus to Iran, replenish Israeli troops and put greater pressure on Hamas to release the hostages that were captured <a href="https://www.benzinga.com/news/23/10/35136071/israel-under-siege-unprecedented-hamas-attack-sparks-intense-clashes-netanyahu-says-we-are-at-war">on Oct. 7, 2023</a>.
See Also: <a href="https://www.benzinga.com/24/11/42198266/crude-oil-moves-lower-dicks-sporting-goods-earnings-top-views">Crude Oil Moves Lower; Dick&#8217;s Sporting Goods Earnings Top Views</a>
Why It Matters: Not everyone is so confident the cease-fire will work.
Per the <a href="https://www.nytimes.com/live/2024/11/26/world/israel-hezbollah-lebanon-cease-fire">New York Times</a>, Israel&#8217;s national security minister Itamar Ben-Gvir stressed the need for a "security zone" inside Lebanon to defend against Hezbollah. Otherwise, the two countries risk another war in the future, he said. 
Ben-Gvir did not indicate that a cease-fire decision would cause him to leave Netanyahu's coalition.
<h3 class="wp-block-heading">Market Reactions</h3>
Oil prices, as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), were down 0.47% at last check Tuesday. Israeli stocks, as monitored through the VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) are up 22.5% year-to-date.
Other oil ETFs were in the red at last check Tuesday afternoon.
ProShares Ultra Bloomberg Crude Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCO#NYSE">UCO</a>) fell by 0.62%, SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) decreased by 0.94%, and MicroSectorsTM Oil &amp; Gas Exploration &amp; Production 3X Leveraged ETNs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILU#NYSE">OILU</a>) saw a 0.84% drop, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42198583/will-trump-lead-us-into-trade-war-with-mexico-president-claudia-sheinbaum-rebukes-threats">Will Trump Lead US Into Trade War With Mexico? President Claudia Sheinbaum Rebukes Threats</a></li>
</ul>
Image: Shutterstock.

Sector ETFs

Commodities

Politics

Global

ETFs

OILU

Netanyahu Backs Cease-Fire Deal With Hezbollah, Israeli Hardliner Calls For 'Security Zone' Inside Lebanon

Target shares are trading lower after Daiwa Capital downgraded the stock from Outperform to Neutral.

Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX">ACB</a>), announced on Tuesday developments in cannabis science from Aurora&#8217;s research and genetics facility, Aurora Coast.
The latest innovations from the Canadian medical cannabis giant include:
<ul>
<li>Aurora &#x7C; CBD Varius (1g, 510 Cartridge);</li>
<li>MedReleaf (Strains For Heroes) &#x7C; Esprit De Corps (5g and 15g); a premium sativa (THC: 20-29%, CBD: 0-1%), developed under the Strains For Heroes initiative by Aurora with direct feedback from Veteran patients;</li>
<li>MedReleaf &#x7C; Sedamen (1g, 510 Cartridge) in a higher THC format;</li>
<li>MedReleaf &#x7C; Noculus (5g and 15g); an ultra-high potency indica, featuring THC levels between 25-31% and CBD content from 0-1%; and</li>
<li>WMMC &#x7C; Seasonal Stash &#8211; Frosted Alpine (10g); a limited-grown hybrid strain (THC: 24-30%; CBD: 0-1%).</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41358918/aurora-cannabis-launches-innovative-thc-oil-products-in-australia-to-meet-diverse-patient-needs">Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs</a> 
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
&#8220;As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility,&#8221; Lana Culley, vice president of science and innovation at Aurora. &#8220;We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis.&#8221;
The latest update from Aurora comes on the heels of its recently revealed lineup of innovations from Greybeard, San Rafael '71 and <a href="https://www.benzinga.com/news/retail-sales/24/11/42098974/canopy-growth-aurora-and-another-cannabis-giant-unveil-product-innovations-heres-whats-new">Tasty's brands for Canadian consumers.</a>
Aurora reported its second quarter financial results, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same <a href="https://www.benzinga.com/markets/cannabis/24/11/41774692/aurora-cannabis-reports-strong-q2-growth-driven-by-international-medical-marijuana-sales">period last year.</a>
The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/02/37365341/uk-medical-cannabis-market-gets-boost-with-aurora-and-script-assist-collaboration">UK Medical Cannabis Market Gets Boost With Aurora And Script Assist Collaboration</a></li>
</ul>
<h3 class="wp-block-heading">ACB Price Action</h3>
Aurora's shares traded 3.28% lower at $4.42 per share at the time of writing on Tuesday morning.

TSX:ACB

Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans

In the current market session, Copa Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>) share price is at $95.10, after a 0.97% increase. Moreover, over the past month, the stock decreased by 4.90%, but in the past year, went up by 0.43%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1732651221_0.png" alt="Past Year Chart" />

<h3>Evaluating Copa Holdings P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 15.28 in the Passenger Airlines industry, Copa Holdings Inc. has a lower P/E ratio of 6.23. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732651221_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Copa Holdings

Allstate shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $206 to $244.

Suncor Energy Says Shortly After 11:00 a.m. On Nov. 26, Sarnia Refinery Experienced Operational Issue In One Of Its Units; In Process Of Restoring Unit To Normal Operating State, Visible Plume, Potential Odor May Have Been Detected Beyond Sarnia Refinery Fence Line

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12154442?requestToken=eyJzdWIiOiJmNTQyNzdhZi0zYjJjLTQ5YzUtOTU0MS1mZDVhN2VmYzJmYzMiLCJ2ZXIiOiJhZWYxZWMwNC1hYTFkLTQ1M2QtYWMxOS1hMjZkNTIyYzdhYjUiLCJleHAiOjB9" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12154442?requestToken=eyJzdWIiOiJmNTQyNzdhZi0zYjJjLTQ5YzUtOTU0MS1mZDVhN2VmYzJmYzMiLCJ2ZXIiOiJhZWYxZWMwNC1hYTFkLTQ1M2QtYWMxOS1hMjZkNTIyYzdhYjUiLCJleHAiOjB9">https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12154442?requestToken=eyJzdWIiOiJmNTQyNzdhZi0zYjJjLTQ5YzUtOTU0MS1mZDVhN2VmYzJmYzMiLCJ2ZXIiOiJhZWYxZWMwNC1hYTFkLTQ1M2QtYWMxOS1hMjZkNTIyYzdhYjUiLCJleHAiOjB9</a>

WKHS

Workhorse Group Granted U.S. Patent US 12154442 B2 For "UAV DELIVERY CONTROL SYSTEM FOR UAV DELIVERY OF PACKAGES"

A game show from popular YouTuber MrBeast has a first-look trailer and a premiere date that could put Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) in direct competition with Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) as two of the most anticipated shows will release a week apart on <a href="https://www.benzinga.com/topic/streaming">competing streaming platforms.</a>
What Happened: With 332 million subscribers on YouTube, MrBeast (aka Jimmy Donaldson) is the <a href="https://www.benzinga.com/general/entertainment/24/07/39720279/mrbeast-celebrates-youtube-record-with-new-video-featuring-50-content-creators-competing-fo">most followed person</a> on the Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) owned video platform.
Viewers frequently flock to the content creator's challenge videos, especially those comparing what $1 can buy versus large sums of money. A recent example, "$1 vs $50,000 Experiences," has garnered 111 million views in just three weeks.
Next month, fans of MrBeast will likely be tuning into his next venture, but they won't be using YouTube.
MrBeast has a <a href="https://www.benzinga.com/general/entertainment/24/03/37809533/mrbeast-confirms-beast-games-on-amazon-prime-video-with-1-000-contestants-5m-prize-its-gonn">new game show</a>, Beast Games, which will be available exclusively on Prime Video, Amazon&#8217;s streaming platform.
The new game show premieres on Dec. 19 and will have 10 episodes. In each episode, 1,000 players will compete in a winner-take-all competition across multiple challenges for a $5 million prize, as <a href="https://variety.com/2024/tv/news/mrbeast-beast-games-premiere-date-prime-video-trailer-1236222911/">reported </a>by Variety.
"I spent over a year creating this 10 episode competition series, breaking 40 world records, building the craziest sets in entertainment history," MrBeast <a href="https://x.com/MrBeast/status/1861121958122770860">tweeted</a>. "I poured everything I have into this show."
Amazon previously called "Beast Games" the "world's largest live gameshow" with the "biggest single prize in the history of television and streaming."
Read Also: <a href="https://www.benzinga.com/general/social-media/24/03/37836042/mrbeast-vs-elon-musk-youtuber-says-x-is-not-there-for-video-yet-they-need-a-year-or-two-to-b">MrBeast Vs. Elon Musk: YouTuber Says X Is &#8216;Not There&#8217; For Video Yet, &#8216;They Need A Year Or Two To Build It Out&#8217;</a>
Why It's Important: The Dec. 19 release date will see the first two episodes of "Beast Games" hit Prime Video, with the other episodes to follow on a weekly basis.
This means that "Beast Games" hits streaming platforms one week before Netflix releases the highly anticipated second season of the smash hit "Squid Game," which<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41123711/netflix-stock-could-get-boost-from-nfl-games-squid-game-season-2-analyst-says-conte"> premieres on Dec. 26.</a>
While "Beast Games" is not a direct replica of "Squid Game," Variety noted some similarities to the games and outfits featured in the Netflix show. MrBeast is, of course, not new to paying tribute to "Squid Game" as he previously created "Squid Game in Real Life," a real-life recreation of the challenges from the game, minus the deaths, with the winner getting $456,000.
MrBeast <a href="https://www.benzinga.com/general/entertainment/24/01/36743469/mrbeast-could-be-bringing-reality-competitions-to-amazon-prime-video-why-this-is-a-miss-for">previously said</a> that other streaming platforms were in talks for the show, but ultimately he went with Amazon.
"Amazon will give us the most creative control. Other platforms didn't. There's a reason we went with Amazon."
While he wouldn't name other companies, Netflix may have been in the running. MrBeast has expressed some hostility towards Netflix for not being involved with the streaming company's reality show version of "Squid Game" called "Squid Game: The Challenge."
&#8220;I&#8217;m not involved. Kind of funny because I learned so much from my filming of this and I probably could have helped them immensely (and would have done it for free haha),&#8221; MrBeast previously said of Netflix&#8217;s reality show.
MrBeast said he watched episodes of <a href="https://www.benzinga.com/general/entertainment/23/11/35991961/squid-game-reality-show-dominates-week-heres-how-many-people-watched-how-it-helped-bring-or" target="_blank" rel="noreferrer noopener">Netflix&#8217;s reality competition</a> based on &#8220;Squid Game&#8221; but did not finish the series. The content creator said the reality competition did a good job building up characters, but also had moments when nothing progressed. Netflix's reality competition had a cash prize of $4.56 million, a record MrBeast is set to break.
The &#8220;Squid Game&#8221; video is currently MrBeast&#8217;s most-watched on YouTube, with 671 million views.
The new "Beast Games" show comes with pending lawsuits from contestants against MrBeast, his production company and Amazon. The lawsuit claims that medical care, food and sleep were not provided for the contestants or minimum wages. Alleged sexual harassment and dangerous conditions are also listed as part of the lawsuits.
MrBeast said the claims from the lawsuit have been "blown out of proportion" in a post on X. The content creator said there is behind the scenes footage that will show the conditions, but it can't be released before the show airs due to spoilers.
"Beast Games" is part of Amazon's increased focus on game shows, with "Are You Smarter Than A Celebrity?" featuring host Travis Kelce premiering in October and the upcoming "Pop Culture Jeopardy!" with host Colin Jost premiering on Dec. 4.
AMZN Price Action: Amazon stock is up 2.6% to $206.85 on Tuesday versus a 52-week trading range of $142.81 to $215.90. Amazon stock is up 37.6% year-to-date in 2024.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Beast Games - Teaser Trailer &#x7C; Prime Video" width="500" height="281" src="https://www.youtube.com/embed/2lyCZnx71ps?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/05/38860861/amazon-betting-on-game-shows-for-streaming-growth-mrbeast-travis-kelce-pop-culture-jeopardy">Amazon Betting On Game Shows For Streaming Growth: MrBeast, Travis Kelce, Pop Culture Jeopardy And More</a></li>
</ul>
Image created using artificial intelligence via Dall-E.

Entertainment

AMZN

GOOG

GOOGL

NFLX

Amazon Prime Vs. Netflix: MrBeast Game Show Arrives Dec. 19, 'Squid Game' Season 2 Drops 1 Week Later

Maximus Shares Halted On Circuit Breaker To The Downside, Stock Now Down -0.77%

<a href="https://press.aboutamazon.com/aws/2024/11/philips-and-aws-expand-strategic-collaboration-to-advance-healthsuite-cloud-services-and-power-generative-ai-workflows">https://press.aboutamazon.com/aws/2024/11/philips-and-aws-expand-strategic-collaboration-to-advance-healthsuite-cloud-services-and-power-generative-ai-workflows</a>
<a href="http://www.philips.com/newscenter">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)), a global leader in health technology, today announced the expansion of its strategic collaboration with Amazon Web Services (AWS) to offer Philips' integrated diagnostics portfolio in the cloud, including radiology, digital pathology, cardiology [1], and AI advanced visualization [1] solutions. The collaboration aims to unify diagnostic workflows, improving access to critical insights and driving better outcomes across clinical specialties. Philips has already successfully transitioned over 150 sites across North America and Latin America to <a href="https://www.usa.philips.com/healthcare/campaign/cloud-healthsuite-imaging">Philips HealthSuite Imaging</a> on AWS and is building on its collaboration with AWS to accelerate the migration of health systems to the cloud, and will expand to include customer cloud migrations in Europe.
<h2>Cloud Capabilities for Integrated Diagnostics</h2>
Philips offers scalable healthcare informatics solutions by leveraging industry-leading cloud availability, reliability and security from AWS. Philips' cloud-based solutions will offer a unified view of patient data from diverse diagnostic sources, including radiology images, digital pathology slides, and other clinical records to support care team collaboration and optimize workflows. Clinicians also benefit from remote access to diagnostic, reporting, and workflow orchestration tools, which can enhance diagnostic capabilities across healthcare imaging, from diagnosis to treatment and follow-up.
"The collaboration between Philips and AWS gives healthcare providers scalable, secure-by-design cloud-enabled solutions to accelerate healthcare innovation," said Matt Garman, CEO of AWS. "Combining Philips' healthcare informatics portfolio with AWS generative AI capabilities gives clinicians access to imaging insights so they can deliver more effective and efficient care to patients anywhere, anytime, with best-in-class security and privacy."
<h2>The Future of Workflows with Generative AI</h2>
As healthcare providers continue to face significant challenges, Philips works closely with clinicians to develop innovative ways to address the increasing clinical demands. By automating routine tasks and optimizing workflows, clinicians would be able to dedicate more time to image interpretation, consultations, and patient interactions. Philips aims to create robust and scalable generative AI applications that leverage state-of-the-art foundation models from Amazon Bedrock, and seamlessly integrate into clinical workflows. In the future, these AI applications may reduce administrative burdens and time-consuming repetitive tasks, helping clinicians focus their expertise where it matters most – in critical decision-making.
One example of how Philips is exploring generative AI as part of its innovation roadmap is through conversational reporting, allowing clinicians to use conversational language to convert findings into structured reports, which can then be reviewed. These capabilities can help construct and revise reports in real-time, add diagnostic impressions, and flag potential inconsistencies. Generative AI has the potential to reduce report editing time, while maintaining high quality by integrating patient histories and clinical context into the final diagnostic report. Optimized reporting could help lead to quicker diagnosis and support better overall quality of care.
"Given the tremendous increase not only in patient volumes, but also in the complexity and number of images per study, radiologists need a tool that limits the distractions of dictation while at the same time increasing accuracy," said Edward Steiner, Chief and Medical Director, The York/WellSpan Advanced Prostate Care Center, USA. "With Philips' concept of ambient reporting using generative AI, you simply could speak in a conversational tone and a structured report is generated within seconds. My estimate is a 15 to 20 percent increase in efficiency, and this is just the start."
"Philips' cloud-based healthcare informatics solutions allow us to drive better outcomes across clinical disciplines, including radiology, digital pathology and cardiology. We're working closely with clinicians to ensure workflows become more efficient and give back valuable time to healthcare providers," said Roy Jakobs, CEO of Royal Philips. "Collaborating with AWS helps us to innovate faster and deliver better care for more people."
<h2>Healthcare Informatics at RSNA</h2>
Philips will showcase its latest informatics solutions in the Philips booth (#6730) at the Radiological Society of North America Annual Meeting, Dec. 1-4, 2024, in Chicago, USA. For more information, visit <a href="https://www.usa.philips.com/healthcare/about/events-calendar/rsna">Philips at RSNA 2024</a>.

Philips And AWS Expand Strategic Collaboration To Advance HealthSuite Cloud Services And Power Generative AI Workflows

<a href="https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana#:~:text=WASHINGTON%20%E2%80%93%20Formal%20hearing%20proceedings%20regarding,Navy%20Drive%2C%20Arlington%2C%20VA" title="https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana#:~:text=WASHINGTON%20%E2%80%93%20Formal%20hearing%20proceedings%20regarding,Navy%20Drive%2C%20Arlington%2C%20VA">https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana#:~:text=WASHINGTON%20%E2%80%93%20Formal%20hearing%20proceedings%20regarding,Navy%20Drive%2C%20Arlington%2C%20VA</a>.

Biotech

AKAN

CRON

GRWG

IMCC

LFLY

MSOS

SNDL

TLRY

DEA Says Formal Hearing Proceedings Regarding Proposed Rescheduling Of Marijuana Will Begin On Dec 2 At 9:30 a.m. ET

Shares of rail stocks are trading lower. Weakness may be in reaction to President-elect Trump's plans for tariffs on Canada and Mexico.

In the current session, the stock is trading at $23.32, after a 1.63% spike. Over the past month, Old National Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) stock increased by 21.99%, and in the past year, by 57.39%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732650339_0.png" alt="Past Year Chart" />

<h3>A Look at Old National P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 19.63 in the Banks industry, Old National Inc. has a lower P/E ratio of 13.9. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732650339_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Price Over Earnings Overview: Old National

Cryptocurrency markets are trading lower on Tuesday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$91,912.69&nbsp;</td>
<td>-2.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,277.87</td>
<td>-4.8%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$226.08</td>
<td>-5.1%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3746</td>
<td>-6.8%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002385</td>
<td>-6.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 77.4% and daily active addresses up by 16.4%. Transactions greater than $100,000 are up from 9,585 to 13,037 in a single day. Exchanges netflows are up by 858.2%.</li>
<li>Coinglass data reports 193,074 traders were liquidated in the past 24 hours for $590.74 million.</li>
<li>CryptoQuant <a href="https://x.com/cryptoquant_com/status/1861467958851289158">noted</a> long-term holders offloaded 728,000 BTC in the past 30 days, the highest sell-off since April.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42183963/microstrategy-coinbase-and-other-bitcoin-linked-stocks-tumble-as-btcs-march-to-100000-stalls">MicroStrategy, Coinbase, And Other Bitcoin-Linked Stocks Tumble As BTC&#8217;s March To $100,000 Stalls</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42196910/pantera-bitcoin-fund-hits-1000x-return-predicts-btc-at-740000-by-2028">Pantera Bitcoin Fund Hits 1,000X Return, Predicts BTC At $740,000 By 2028</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42181280/crypto-billionaire-justin-sun-pledges-30m-investment-in-trump-backed-world-liberty-financial-whats-happening">Crypto Billionaire Justin Sun Pledges $30M Investment In Trump-Backed World Liberty Financial: What&#8217;s Happening?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42198180/dogecoin-gets-its-first-exchange-traded-product-in-sweden">Dogecoin Gets Its First Exchange-Traded Product In Sweden</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42180536/pro-bitcoin-trump-administration-could-see-el-salvador-emerging-as-us-strategic-partner-says-vaneck">Pro-Bitcoin Trump Administration Could See El Salvador Emerging As US &#8216;Strategic Partner,&#8217; Says VanEck</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>)</td>
<td>&nbsp;$0.5954</td>
<td>-18.6%</td>
</tr>
<tr>
<td>Stellar (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xlm/usd">XLM</a>)</td>
<td>&nbsp;$0.4344</td>
<td>-14.9%</td>
</tr>
<tr>
<td>Maker (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mkr/usd">MKR</a>)</td>
<td>&nbsp;$1,689.37&nbsp;</td>
<td>-11.7%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin&#8217;s recent price drop dragging the cryptocurrency market lower, chart analyst Ali Martinez highlights the availability of crypto assets at &#8220;discounts.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Black Friday came early! These are pretty good discounts. <a href="https://t.co/BJFWCdmR2U">pic.twitter.com/BJFWCdmR2U</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1861379672572870988?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to More Crypto Online, Bitcoin's correction remains in progress.
The $92,802 support hasn't been invalidated, meaning bulls could still regain momentum. 
Key support levels <a href="https://x.com/Morecryptoonl/status/1861405295232131425">include</a> $88,650, with additional Fibonacci targets at $85,558 and $77,874 if the downward trend persists.
CoinDesk senior analyst James Van Straten noted a record-breaking $4 billion in Bitcoin panic sales to exchanges, triggering liquidation cascades that allowed smart money to accumulate at discounted prices. Van Straten <a href="https://x.com/btcjvs/status/1861455973854126504">believes</a> the correction, which reached 10%, may now be complete.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History,&#8217; Crypto Surge Following It Was 3 Years Overdue</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$MKR

$SAND

$SHIB

$SOL

$XLM

Bitcoin, Ethereum, Dogecoin Drop Further: 'Black Friday Came Early,' Says Trader Touting 'Good Discounts'

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MariMed (OTCMKTS:<a href="https://investorplace.com/stock-quotes/mrmd-stock-quote/">MRMD</a>) just reported results for the second quarter of 2024.<ul><li>The company did not report any EPS for the quarter.</li><li>The company reported revenue of $40.44 million.</li><li>This was 2.12% better than the analyst estimate for revenue of $39.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mrmd-stock-earnings-marimed-for-q2-of-2024/">MRMD Stock Earnings: MariMed Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MRMD Stock Earnings: MariMed Beats Revenue for Q2 2024

MariMed Inc. (MRMD) Q2 2024 Earnings Call Transcript

MariMed (MRMD) has provided an update. MariMed Inc. has announced Mario Pinho as their new Chief Financial Officer effective August 9, 2024. With n...

MariMed Names Mario Pinho as New CFO, Enhancing Financial Leadership

American views on marijuana effects worsening: Gallup

MariMed (MRMD) announced the start of cannabis product manufacturing in Missouri. MariMed's award-winning products are expected to be available acr...

Marimed commences manufacturing operations in Missouri

InHouse, MariMed's (MRMD), is committed to serving local communities by finding ways to provide support to those in need. The mission continues thi...

Marimed's InHouse launches Help on the Homefront

Here are the major earnings after the close today

MariMed GAAP EPS of $0.00, revenue of $40.6M misses by $1.1M

MariMed Inc. (MRMD) Q3 2024 Earnings Call Transcript

Marimed ( ($MRMD) ) has released its Q3 earnings. Here is a breakdown of the information Marimed presented to its investors. MariMed Inc. is a lead...

MariMed Inc. Reports Third Quarter 2024 Earnings

AAWH

ACAD

ACLS

ADTN

AEVA

ALTO

AMPH

AMPY

AMRK

ANSS

APPS

ARAY

ARQT

ASPN

AYRWF

BBDC

BIRD

CNBS

CRLBF

CURLF

CWBHF

DUOL

ENLC

ETRGF

FLGC

GLASF

GPMT

GTBIF

HCAT

HITI

HRTG

HUBS

IIPR

IONQ

JAZZ

JOBY

JUSHF

KNTK

LAND

LILA

LILAK

LOPE

LUNMF

LYFT

MAPS

MATV

MEOH

MKSI

MTCH

NDLS

NEWT

NMIH

NVGS

PCLOF

PLNH

TCNNF

VRNOF

YCBD

YOLO

Press Releases

MariMed Announces Opening of Second Maryland Dispensary

MariMed's Bubby's Baked Introduces New, Limited-Edition Pumpkin Bread Bites This Autumn

MariMed Commences Adult-Use Sales at Thrive Wellness Dispensary in Tiffin, Ohio

Health Care

MariMed's Betty's Eddies Partners With Keep A Breast Foundation to Promote Breast Cancer Screening Education

MariMed's Nature's Heritage Gives Local Musicians a Chance to be Featured in New Interactive Vape Campaign

MariMed Announces Third Quarter 2024 Earnings Date

MariMed Commences Cultivation Operations in Mt. Vernon, Illinois Grow Facility

MariMed Commences Manufacturing Operations in Missouri

InHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing Challenges

Earnings

MariMed Reports Third Quarter 2024 Earnings

CSE:MRMD

BTIG

シニアアナリストのPablo・Zuanic氏が、マリメド社（OTC:MRMD）CEOのJon Levine氏とのファイヤーサイドチャットを進行し、同社の事業、成長戦略および財務見通しについて透視した。この議論は、大麻投資家にとって有益な情報を提供している。
<h3>強い第2四半期の業績と財務見通し</h3>
Levine氏は、マリメド社が2024年第2四半期に強い<a href="https://www.benzinga.com/markets/cannabis/24/08/40250157/marimed-revenue-grows-10-7-qoq-hires-new-cfo-and-remains-on-track-to-deliver-2024-financial-targ">業績を収め、引き続き年間売上成長率の見通しを5％から7％と維持</a>していると指摘した。業界全般に圧力がかかっているにもかかわらず、マリメド社は、<a href="https://www.benzinga.com/topic/maryland-cannabis">イリノイ州</a>、<a href="https://www.benzinga.com/topic/maryland-cannabis">メリーランド州</a>、およびマサチューセッツ州での卸売業務によって、今年に至るまで11％の成長を遂げている。
Levine氏は「私たちの売上は業界全体を上回り続けており、今年と今後の見通しを達成するための準備が整っています」と語った。
また、マリメド社は中長期的な収益性への寄与を見越して、今年中にもメリーランド州における製造能力を2倍にするといった新施設への投資を行い、このために短期的なマージンとEBITDAの圧力がかかっている。
<h3>主要市場での拡大計画</h3>
マリメド社は、数々の州で事業を拡大している。同社はメリーランド州で第二の店舗を開業する予定で、これがLevine氏が年間で1,000万ドルを上回る売上を見込んでいるという。同社はベティーズ・エディーズ（Betty&#8217;s Eddies）などの人気ブランドをこの四半期末に市場に導入する予定で、ミズーリ州でも加工免許を取得している。
マサチューセッツ州においてもマリメド社は、同社の強いブランド認知度を通じて、市場シェアを拡大している。Levine氏は、「ブランド認知度と製品の品質のおかげで、私たちのマサチューセッツ州での卸売りビジネスは成長を続け、誰もが驚いています」と述べた。
関連記事： <a href="https://www.benzinga.com/markets/cannabis/24/08/40322027/trumps-flip-on-marijuana-legalization-conflicts-with-running-mate-jd-vance-who-does-not-share-th">トランプ氏、大麻解禁を巡る考えが変化 トランプ氏のランニングメイトJDヴァンス氏との間で見解が相違</a>
また、マリメド社はイリノイ州とオハイオ州での小売り事業の拡大にも注力している。同社はイリノイ州で5店舗を運営しており、さらに5店舗を追加する予定である。また、オハイオ州では、州が最近成人向け大麻の販売を開始したため、マリメド社も事業を拡大する準備を整えている。
<h3>M&amp;Aとライセンスを通じた将来の成長</h3>
Levine氏は、マリメド社が進めている企業買収（M&amp;A）とライセンス契約に関する活動についても語った。同社はライセンス料が高すぎないかという点には慎重であるが、<a href="https://www.benzinga.com/topic/ohio-cannabis">オハイオ州</a>、ミズーリ州および他の州での事業拡大の機会を積極的に模索しているという。Levine氏はまた、ニューヨーク州、テキサス州、バージニア州でのライセンス申請についても言及している。
マリメド社は、現在事業を展開していないロードアイランド州やプエルトリコなどの州でのライセンスの取得についても検討している。ただしLevine氏は、マリメド社の製品の高品質と一貫性を維持するためには、適切なパートナーを見つけることが重要であると強調した。
<h3>政治的見通し：大統領選挙と大麻</h3>
一方でLevine氏はファイヤーサイドチャットの中で、大麻の再分類に関する元大統領ドナルド・トランプ氏の最近のコメントについての質問に答えた。 Levine氏は、大麻の再分類についての議論が民主党と共和党の双方で増加していることに関して楽観的な見方を示し、「再分類は次の12か月以内に何らかの形で実現すると思います」と述べた。ただし、Levine氏は政府の行動が鈍いことを認めた。
次の記事を読む： <a href="https://www.benzinga.com/markets/cannabis/24/08/40271940/trump-says-its-hard-to-have-people-all-over-the-jails-for-cannabis-offenses-as-he-hints-at-legal">再分類された大麻に対してトランプ氏、法的処置を取ることを示唆</a>
<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a>
。

Comments

MariMed

ニュース

最新ニュース MariMed (OTC:MRMD) 株価情報

月曜日, 8 12, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル